Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. blood disease
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Blood Disease Articles & Analysis

23 news found

CRISPR Off-Target Analysis Now Available with CD Genomics’ Bioinformatics-Analysis Platform

CRISPR Off-Target Analysis Now Available with CD Genomics’ Bioinformatics-Analysis Platform

In recent years, CRISPR technology has significantly promoted the innovation of gene therapy for blood diseases, tumors, genetic diseases, and other diseases, which has become a powerful tool in the field of scientific research. ...

ByCD Genomics


Structure-Based Search for Novel Antihypercholestrolemic Agents

Structure-Based Search for Novel Antihypercholestrolemic Agents

A high cholesterol level is a well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the National Cholesterol Education Program (NCEP). ...

ByShifa Biomedical Corporation


Novel Modulators of LDL Metabolism

Novel Modulators of LDL Metabolism

DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of ...

ByShifa Biomedical Corporation


Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China

Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China

In the future, we will leverage Fosun Pharma’s advantages in the fields of kidney and blood system diseases and other therapeutic fields to improve the availability of medicines for patients and benefit more Chinese ...

ByShanghai Fosun Pharmaceutical (Group) Co. Ltd.


UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Additionally, a symposium titled, “Cellular senescence and immune response in ocular health and disease,” featured leading researchers in the field who discussed the role of cellular senescence and aging in various eye diseases, as well as promising therapeutic approaches to target this pathway. As demonstrated in preclinical studies, Bcl-xL is highly ...

ByUNITY Biotechnology


Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System

Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System

“Given the accelerating global epidemic of T2D, new approaches are desperately needed in order to reduce disease burden, improve outcomes, and increase value. Despite the availability of a wide variety of therapeutic options, T2D remains a progressive, expensive, debilitating disease. ...

ByFractyl Health


Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes

Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes

“We are committed to rigorously evaluating the safety and effectiveness of Revita in patients with T2D across the spectrum of disease with our Revitalize T2D clinical development program.” About Revita® Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in metabolic ...

ByFractyl Health


Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di

” About Revita® Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in metabolic diseases. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a ...

ByFractyl Health


Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index

Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index

(Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the December 20, 2021 reconstitution. ...

ByBrooklyn ImmunoTherapeutics (BTX)


Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size

Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size

About Revita® Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in metabolic diseases. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a ...

ByFractyl Health


Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis

Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis

Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive ...

ByC2N Diagnostics


Velano raises $15M to go beyond non-invasive blood tests

Velano raises $15M to go beyond non-invasive blood tests

For most of us, getting blood drawn is an unpleasant, but necessary, part of life. For others, though, it’s extremely risky, if not impossible. ...

ByVelano Vascular


IU Philanthropic Venture Fund Invests in Regenerative Medicine Company Vascugen

IU Philanthropic Venture Fund Invests in Regenerative Medicine Company Vascugen

Vascugen is focused on finding therapies to repair human tissue damaged by reduced blood flow due to disease or injury. The company has received additional investment from other Indiana-based investors, including Indianapolis entrepreneur Dr. ...

ByVascugen Inc.


Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine

Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration Developed at IU School of Medicine

Vascuqen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury. ...

ByVascugen Inc.


PTR-MS breath test shows potential for detecting liver disease

PTR-MS breath test shows potential for detecting liver disease

Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS. Elevated levels of limonene in patients have been found to be indicative of a diseased liver. Especially in the UK liver disease has risen sharply over the past few decades and is the third biggest ...

ByIonicon Analytik Ges.m.b.H.


Asthma Awareness Month 2014: NIH Continues its Commitment to Asthma Research

The three main NIH institutes that support and conduct asthma-related research are the National Institute of Environmental Health Sciences (NIEHS); the National Heart, Lung, and Blood Institute (NHLBI); and the National Institute of Allergy and Infectious Diseases (NIAID). ...

ByNational Institute of Environmental Health Sciences (NIEHS)


NIH statement on Asthma Awareness Month

To most effectively manage asthma, we need to address the disproportionate impact of the disease on minorities and families at or below the poverty line. NIH is committed to reducing asthma disparities and improving asthma control for all who live with the disease. The National Heart, Lung, and Blood Institute (NHLBI); National Institute of ...

ByNational Institute of Environmental Health Sciences (NIEHS)


White House Issues Bioeconomy Blueprint Reaffirming Commitment to Biobased Products

White House Issues Bioeconomy Blueprint Reaffirming Commitment to Biobased Products

These include initiatives to encourage federal procurement of an expanded range of biobased products; take better advantage of large pharmaceutical data sets to speed drug development; apply the latest genomics discoveries to identify quickly emerging microbial threats; and accelerate research on non-embryonic stem cells as possible treatments for blood-related and neurological ...

ByBergeson & Campbell, P.C.


White House Issues Bioeconomy Blueprint Reaffirming Commitment to Biobased Products

White House Issues Bioeconomy Blueprint Reaffirming Commitment to Biobased Products

These include initiatives to encourage federal procurement of an expanded range of biobased products; take better advantage of large pharmaceutical data sets to speed drug development; apply the latest genomics discoveries to identify quickly emerging microbial threats; and accelerate research on non-embryonic stem cells as possible treatments for blood-related and neurological ...

ByActa Group


White House issues bioeconomy blueprint reaffirming commitment to biobased products

White House issues bioeconomy blueprint reaffirming commitment to biobased products

These include initiatives to encourage federal procurement of an expanded range of biobased products; take better advantage of large pharmaceutical data sets to speed drug development; apply the latest genomics discoveries to identify quickly emerging microbial threats; and accelerate research on non-embryonic stem cells as possible treatments for blood-related and neurological ...

ByActa Group

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT